Literature DB >> 18223185

Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice.

Fadi N Salloum1, Antonio Abbate, Anindita Das, Jon-Erik Houser, Colin A Mudrick, Ian Z Qureshi, Nicholas N Hoke, Sion K Roy, William R Brown, Shashi Prabhakar, Rakesh C Kukreja.   

Abstract

We tested the hypothesis that chronic treatment with sildenafil attenuates myocardial infarction (MI)-induced heart failure. Sildenafil has potent protective effects against necrosis and apoptosis following ischemia-reperfusion in the intact heart and cardiomyocytes. ICR mice underwent MI by left anterior descending coronary artery ligation and were treated with sildenafil (0.71 mg/kg bid) or saline for 4 wk. Infarct size (IS) was measured 24 h postinfarction, and apoptosis was measured by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. Left ventricular end-diastolic diameter (LVEDD) and fractional shortening (FS) were measured by echocardiography. Sildenafil reduced IS (40.0 +/- 4.6%) compared with that in saline (69.6 +/- 4.1%, P < 0.05). NG-nitro-l-arginine methyl ester, a nitric oxide synthase (NOS) inhibitor (15 mg/kg bid), blocked the protective effect of sildenafil (IS, 60.2 +/- 1.6%, P < 0.05 vs. sildenafil). Western blot analysis revealed a significant increase in endothelial NOS/inducible NOS proteins 24 h post-MI after treatment with sildenafil versus saline. Apoptosis decreased from 2.4 +/- 0.3% with saline to 1.2 +/- 0.1% with sildenafil (P < 0.05) on day 7 and from 2.0 +/- 0.2% with saline to 1.2 +/- 0.1% with sildenafil on day 28 (P < 0.05), which was associated with an early increase in the Bcl-2-to-Bax ratio. LVEDD increased from baseline value of 3.6 +/- 0.1 to 5.2 +/- 0.2 and to 5.5 +/- 0.1 mm on days 7 and 28, respectively, with saline (P < 0.05) but was attenuated to 4.4 +/- 0.2 and 4.4 +/- 0.1 mm following sildenafil treatment on days 7 and 28, respectively (P > 0.05 vs. baseline). FS significantly improved post-MI with sildenafil. A marked decline in cardiac hypertrophy was observed with sildenafil, which paralleled a reduction in pulmonary edema. Survival rate was lower with saline (36%) compared with sildenafil (93%, P < 0.05). Sildenafil attenuates ischemic cardiomyopathy in mice by limiting necrosis and apoptosis and by preserving left ventricular function possibly through a nitric oxide-dependent pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223185     DOI: 10.1152/ajpheart.91438.2007

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  89 in total

1.  Beetroot juice reduces infarct size and improves cardiac function following ischemia-reperfusion injury: Possible involvement of endogenous H2S.

Authors:  Fadi N Salloum; Gregory R Sturz; Chang Yin; Shabina Rehman; Nicholas N Hoke; Rakesh C Kukreja; Lei Xi
Journal:  Exp Biol Med (Maywood)       Date:  2014-10-30

Review 2.  cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action.

Authors:  Sharron H Francis; Jennifer L Busch; Jackie D Corbin; David Sibley
Journal:  Pharmacol Rev       Date:  2010-09       Impact factor: 25.468

3.  The role of cGMP-dependent protein kinase in controlling cardiomyocyte cGMP.

Authors:  Sharron H Francis
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

4.  Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil: A Long Acting Phosphodiesterase-5 Inhibitor.

Authors:  Saisudha Koka; Rakesh C Kukreja
Journal:  Mol Cell Pharmacol       Date:  2010

5.  PDE5 inhibitors enhance the lethality of standard of care chemotherapy in pediatric CNS tumor cells.

Authors:  Jane L Roberts; Laurence Booth; Adam Conley; Nichola Cruickshanks; Mark Malkin; Rakesh C Kukreja; Steven Grant; Andrew Poklepovic; Paul Dent
Journal:  Cancer Biol Ther       Date:  2014-03-20       Impact factor: 4.742

6.  Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide.

Authors:  Fadi N Salloum; Vinh Q Chau; Nicholas N Hoke; Antonio Abbate; Amit Varma; Ramzi A Ockaili; Stefano Toldo; Rakesh C Kukreja
Journal:  Circulation       Date:  2009-09-15       Impact factor: 29.690

7.  Chronic in vivo angiotensin II administration differentially modulates the slow delayed rectifier channels in atrial and ventricular myocytes.

Authors:  Dimitar P Zankov; Fadi N Salloum; Min Jiang; Gea-Ny Tseng
Journal:  Heart Rhythm       Date:  2018-08-01       Impact factor: 6.343

Review 8.  Cardioprotective actions of cyclic GMP: lessons from genetic animal models.

Authors:  Christian F Deschepper
Journal:  Hypertension       Date:  2009-12-14       Impact factor: 10.190

9.  Concerted regulation of cGMP and cAMP phosphodiesterases in early cardiac hypertrophy induced by angiotensin II.

Authors:  Walid Mokni; Thérèse Keravis; Nelly Etienne-Selloum; Alison Walter; Modou O Kane; Valérie B Schini-Kerth; Claire Lugnier
Journal:  PLoS One       Date:  2010-12-03       Impact factor: 3.240

10.  ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice.

Authors:  Anindita Das; Fadi N Salloum; Lei Xi; Yuan J Rao; Rakesh C Kukreja
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-03-13       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.